XRTX

XORTX Therapeutics Inc. (XRTX) | Rumor.io

XORTX Therapeutics

XRTX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,190

Bullish sentiment (50-day avg)91%

Price to earnings ratio7.53

Market capitalization3.1M

Earnings per share-2.6

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-2.7M

Social

What share of all stock conversation is about XRTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Sep 18

XORTX Therapeutics Inc. announced plans to submit an IND to FDA for its XRx-026 gout program, targeting a $700M+ U.S. gout market opportunity.
Shares of XORTX jumped 15.66% to $1.92, with the primary catalyst being the company's announcement.
The stock's price surged 68% from $1.71 to $2.65 in 5h 45m, with a low float and high volume.

Generated by AI

Sentiment

Of the messages about XRTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +25	90.91%	87.01% -4.24
Bearish	—	0% -25	9.09%	12.99% +4.24

Bullish· Apr 21

$XRTX has a strong risk/reward setup due to its beaten-down chart, making it a good opportunity for a potential breakout.
The company needs to break through the $3.70 level to continue its upward momentum, which could be facilitated by high trading volume.
$XRTX has a potential to reach the mid-3s, requiring patience from investors, but showing promise for further price appreciation.

Bearish· Apr 21

XORTX Therapeutics has regained Nasdaq compliance after a 1-for-5 reverse stock split, but its cash reserves are low at $600k, and it may need to issue an offering soon.
The company's quarterly losses of $500-800k are significant, and its cash situation is a concern.
XORTX's stock price has been volatile, with some traders questioning its legitimacy and others expecting a potential squeeze or big spike.

Generated by AI

Topics

Of the messages about XRTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	21.13%	31.46%	31.22%
Analysts	—	39.44%	31.46%	18.03%
Technical Analysis	—	0%	5.62%	32.05%
Macro	—	39.44%	31.46%	18.03%
Controversies	—	0%	0%	0.67%
Earnings	—	0%	0%	0%

Announcements· Oct 17

XORTX Therapeutics Inc. (XRTX) acquired a patented small molecule renal anti-fibrotic therapeutic program from Vectus Biosystems for $3.0M.
The acquired program includes novel compound VB4-P5, which has strong preclinical evidence and potential to address significant unmet needs in rare and large-market kidney diseases.
XRTX's stock surged on the acquisition, with shares spiking 43% and expanding its renal therapy pipeline.

Technical Analysis· Oct 17

$XRTX has shown significant volume with almost 50 million shares traded, indicating a strong market interest.
A potential breakout is being considered, with a possible target of $1.40 if the EMA12 breaks above the EMA5.
The stock has broken out of a descending wedge and is showing signs of a strong bullish momentum, with a high volume surge and a RSI breaking barriers.

Generated by AI

Community

Of the messages about XRTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	6.29%	6.01%	30.89%
Newcomers	100%	93.71%	93.99%	69.11%

Regulars· Apr 21

$XRTX is currently trading at $3.00-$3.58, with a notable 40% move up in the past, and is coming off its final blast through $3.50.
The stock is fading slightly, but if it can reclaim its VWAP after the bell, it may be a good entry opportunity; if it stays underneath VWAP, it won't be considered.
$XRTX has regained NASDAQ compliance and needs to break the pennant and resistance at $3.39 to continue its upward momentum.

Newcomers· Sep 18

The company XORTX Therapeutics Inc. has announced its plan to submit an IND to FDA for its XRx-026 program to treat gout, targeting a large US market worth over $700 million.
XRTX stock has shown significant movement, rising by +68% from $1.71 to $2.65 in 5 hours and 45 minutes, with a low float of 1.2 million shares and high volume of 1.7 million shares.
Despite the recent good news, some analysts believe it's impossible for the price to rise due to the company exercising warrants, which could negatively impact the stock price.

Generated by AI

Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, outlines its anticipated Investigational New Drug applica

12d agoYahoo Finance

XORTX Therapeutics Shares Rise 16.11% After Hours - XORTX Therapeutics (NASDAQ:XRTX)

19d agoBenzinga

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ● CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the launch of production of drug material and tablet manufacturing to support t

19d agoYahoo Finance UK

XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile

Detailed price information for Xortx Therapeutics Inc (XRTX-Q) from The Globe and Mail including charting and trades.

21d agoThe Globe and Mail

XORTX Re-Engages Investor Relations Program

CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ('XORTX ' or the “Company ”) announces that, following completion o...

21d agomarkets.businessinsider.com

XORTX Announces Termination and Postponement of Investor Relations Program

CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “IR Agreement”). The IR Agreement had a 90-day term

1mo agoYahoo Finance

Also Discussed

Investors talking about XRTX also mention

#	Name	Attention
1	SciSparc Ltd.SPRC	0%+0
2	Better Therapeutics, Inc.BTTX	0%new
3	Tenon Medical, Inc.TNON	0%new
4	Golden Sun Technology Group LimitedGSUN	0%new
5	LIPO - Lipella Pharmaceuticals Inc.	——
6	SaverOne 2014 Ltd. ADRSVRE	0%new
7	NFT Ltd. Class A Ordinary ShareMI	0%+0
8	GRFX - Graphex Group Limited	——
9	TCBP - TC Biopharm (Holdings) Plc	——
10	ParaZero Technologies Ltd.PRZO	0%+0

XORTX Therapeutics Inc.

Healthcare
Biotechnology

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing therapies for gout, progressive kidney disease, and other disorders linked to elevated uric acid and abnormal purine metabolism. Its current pipeline includes programs for gout, autosomal dominant polycystic kidney disease, acute kidney injury associated with respiratory virus infections, and type 2 diabetic nephropathy. The company’s research centers on uric acid-lowering and xanthine oxidase-targeted approaches designed to address conditions ranging from rare kidney diseases to broader metabolic and renal disorders. Based in Calgary, Canada, XORTX Therapeutics Inc. operates as a biotechnology and pharmaceutical developer with an emphasis on advancing drug candidates through clinical development and commercialization in specialized disease areas.

Website

Location

3710 – 33rd Street NW

Calgary, AB, T2L 2M1

Canada

Social

What share of all stock conversation is about XRTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Sep 18

XORTX Therapeutics Inc. announced plans to submit an IND to FDA for its XRx-026 gout program, targeting a $700M+ U.S. gout market opportunity.
Shares of XORTX jumped 15.66% to $1.92, with the primary catalyst being the company's announcement.
The stock's price surged 68% from $1.71 to $2.65 in 5h 45m, with a low float and high volume.

Generated by AI

Sentiment

Of the messages about XRTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +25	90.91%	87.01% -4.24
Bearish	—	0% -25	9.09%	12.99% +4.24

Bullish· Apr 21

$XRTX has a strong risk/reward setup due to its beaten-down chart, making it a good opportunity for a potential breakout.
The company needs to break through the $3.70 level to continue its upward momentum, which could be facilitated by high trading volume.
$XRTX has a potential to reach the mid-3s, requiring patience from investors, but showing promise for further price appreciation.

Bearish· Apr 21

XORTX Therapeutics has regained Nasdaq compliance after a 1-for-5 reverse stock split, but its cash reserves are low at $600k, and it may need to issue an offering soon.
The company's quarterly losses of $500-800k are significant, and its cash situation is a concern.
XORTX's stock price has been volatile, with some traders questioning its legitimacy and others expecting a potential squeeze or big spike.

Generated by AI

Topics

Of the messages about XRTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	21.13%	31.46%	31.22%
Analysts	—	39.44%	31.46%	18.03%
Technical Analysis	—	0%	5.62%	32.05%
Macro	—	39.44%	31.46%	18.03%
Controversies	—	0%	0%	0.67%
Earnings	—	0%	0%	0%

Announcements· Oct 17

XORTX Therapeutics Inc. (XRTX) acquired a patented small molecule renal anti-fibrotic therapeutic program from Vectus Biosystems for $3.0M.
The acquired program includes novel compound VB4-P5, which has strong preclinical evidence and potential to address significant unmet needs in rare and large-market kidney diseases.
XRTX's stock surged on the acquisition, with shares spiking 43% and expanding its renal therapy pipeline.

Technical Analysis· Oct 17

$XRTX has shown significant volume with almost 50 million shares traded, indicating a strong market interest.
A potential breakout is being considered, with a possible target of $1.40 if the EMA12 breaks above the EMA5.
The stock has broken out of a descending wedge and is showing signs of a strong bullish momentum, with a high volume surge and a RSI breaking barriers.

Generated by AI

Community

Of the messages about XRTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	6.29%	6.01%	30.89%
Newcomers	100%	93.71%	93.99%	69.11%

Regulars· Apr 21

$XRTX is currently trading at $3.00-$3.58, with a notable 40% move up in the past, and is coming off its final blast through $3.50.
The stock is fading slightly, but if it can reclaim its VWAP after the bell, it may be a good entry opportunity; if it stays underneath VWAP, it won't be considered.
$XRTX has regained NASDAQ compliance and needs to break the pennant and resistance at $3.39 to continue its upward momentum.

Newcomers· Sep 18

The company XORTX Therapeutics Inc. has announced its plan to submit an IND to FDA for its XRx-026 program to treat gout, targeting a large US market worth over $700 million.
XRTX stock has shown significant movement, rising by +68% from $1.71 to $2.65 in 5 hours and 45 minutes, with a low float of 1.2 million shares and high volume of 1.7 million shares.
Despite the recent good news, some analysts believe it's impossible for the price to rise due to the company exercising warrants, which could negatively impact the stock price.

Generated by AI

XORTX Therapeutics

Social

Sep 18

Bullish· Apr 21

Bearish· Apr 21

Announcements· Oct 17

Technical Analysis· Oct 17

Regulars· Apr 21

Newcomers· Sep 18

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

XORTX Therapeutics Shares Rise 16.11% After Hours - XORTX Therapeutics (NASDAQ:XRTX)

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile

XORTX Re-Engages Investor Relations Program

XORTX Announces Termination and Postponement of Investor Relations Program

Also Discussed

XORTX Therapeutics Inc.

Company Information

Location

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

XORTX Therapeutics Shares Rise 16.11% After Hours - XORTX Therapeutics (NASDAQ:XRTX)

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile

XORTX Re-Engages Investor Relations Program

XORTX Announces Termination and Postponement of Investor Relations Program

Also Discussed

Social

Sep 18

Bullish· Apr 21

Bearish· Apr 21

Announcements· Oct 17

Technical Analysis· Oct 17

Regulars· Apr 21

Newcomers· Sep 18